Browse > Article
http://dx.doi.org/10.24304/kjcp.2020.30.3.177

The Opinion of Experts and Stakeholder on Introduction of Orphan or Anticancer Drugs Funding Program  

Kim, Sujin (Department of Research, Health Insurance Review & Assessment Service)
Jung, Seungyeon (Korea Institute for Pharmaceutical Policy Affairs)
Kim, Dong-Sook (Department of Research, Health Insurance Review & Assessment Service)
Publication Information
Korean Journal of Clinical Pharmacy / v.30, no.3, 2020 , pp. 177-184 More about this Journal
Abstract
Background & objective: The Korean government has expanded its benefit coverage to enhance patients' access to orphan drugs and cancer medicines. However, the number of new drugs whose indications were not applied to reimbursement in health insurance was increased. This study aimed to understand the perspectives of experts and various stakeholders on the introduction of a new funding program for cancer treatment and orphan drugs. Methods: We conducted email surveys comprising 19 questions, from September 9 to 26, 2016. We distributed questionnaires to members of the Pharmaceutical Benefit Appraisal Committee and Cancer Assessment Committee. We also conducted a qualitative study through group interviews with stakeholders, including pharmaceutical companies and some patient groups for diseases. Results: A total of 35 survey respondents recommended the introduction of a funding program for orphan drugs, whereas 66% recommended the launch of funding for anticancer drugs. In addition, most pharmaceutical companies and patient groups recommended the introduction of new funding programs targeting patients with cancer and rare diseases. However, some participants asserted that it would be more appropriate to modify the existing reimbursement scheme than launch new funding. Conclusion: This study concluded that introducing new funding needs a social consensus to relieve financial hardships at the patient level.
Keywords
Benefit coverage; funding; survey; interview;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wagner AK, Graves AJ, Reiss SK, LeCates R, Zhang F, Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: Results from the World Health Survey. Health Policy 2011;100(2-3):151-8.   DOI
2 Ministry of Health and Welfare. All of medical not covered treatment will be applied to health insurance. Press release on August 9, 2017. Available from https://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=340973. Accessed June 11, 2019.
3 Ministry of Health and Welfare. Treatment on cancer, cardiology, cerebrovascular, and orphan disease will be resolved using health insurance. Press release on March 29, 2013. Available from https://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=284199. Accessed June 11, 2019.
4 Ministry of Health and Welfare. Expansion of health insurance coverage for medicines of four diseases. Press release on December 31, 2013. Available from https://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=295049. Accessed June 11, 2019.
5 Health Insurance Review & Assessment Service. Health Insurance Benefit Criteria of Pharmaceuticals. Wonju: HIRA, September 1, 2019. Available from http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030023010000&brdScnBltNo=4&brdBltNo=45587&pageIndex=1. Accessed June 11, 2019.
6 Kim D, Kim HL, Yang DW, Kang E, Kim J, Bae E. Qualitative study of cancer survivors' needs related to survival stages. Health and Social Welfare Review 2019;39(4):356-95.   DOI
7 Legislative Investigation Office of National Assembly. The issue analysis report of 2019 Parliamentary audit. Seoul: National Assembly, 2020. Available from https://www.nars.go.kr/report/view.do?page=1&cmsCode=CM0019&categoryId=&searchType=&searchKeyword=&brdSeq=25681. Accessed June 11, 2019.
8 Australian Department of Health. About the PBS. Available from http://www.pbs.gov.au/info/about-the-pbs#What_is_the_PBS. Accessed October 17, 2016.
9 Australian Department of Health. Life Saving Drugs Program (LSDP) Program-Life Saving Drugs Program Criteria and Conditions. Available from http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-criteria. Accessed October 11, 2016.
10 Belgian Health Care Knowledge Centre (KCE). Optimization of the operational processes of the Special Solidarity Fund. KCE reports 133C. 2010. Available from https://kce.fgov.be/sites/default/files/page_documents/kce_133c_special_solidarity_fund.pdf. Accessed July 27, 2016.
11 NHS England. About the NHS. Available from http://www.nhs.uk/NHSEngland/thenhs/about/Pages/overview.aspx. Accessed July 27, 2016.
12 Cancer Research UK. Cancer Drugs Fund. Available from http://www.cancerresearchuk.org/about-cancer/cancers-in-general/cancerquestions/cancer-drugs-fund. Accessed July 7, 2016.
13 Jung SY, Kim SJ, Kim DS. The review of orphan or anticancer drugs funding programs from foreign countries' experiences. Yakhakhoeji 2017;61(2):100-8.
14 Kim DS, Jeon HK, Kim BS, Kim SO. Expert opinion survey on the feasibility of introducing a selective benefit on the drug use off-thestandard. The Korean Journal of Health Economics and Policy 2017;23(2):17-35.
15 Colaizzi PF. Psychological research as the phenomenologist views it. In: Valle RS and King M, eds. Existential phenomenological alternatives for psychology. Oxford University Press, 1978: 48-71.